Publications by authors named "Robert K Stuart"

47Publications

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

J Clin Oncol 2018 09 19;36(26):2684-2692. Epub 2018 Jul 19.

Jeffrey E. Lancet, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Geoffrey L. Uy, Washington University School of Medicine, St Louis, MO; Jorge E. Cortes, The University of Texas MD Anderson Cancer Center, Houston, TX; Laura F. Newell, Oregon Health & Science University, Portland, OR; Tara L. Lin, University of Kansas Medical Center, Kansas City, KS; Ellen K. Ritchie, Weill Cornell Medical College, New York; Jonathan E. Kolitz, Northwell Health System, Lake Success; Daniel H. Ryan, University of Rochester, Rochester, NY; Robert K. Stuart, Medical University of South Carolina, Charleston, SC; Stephen A. Strickland, Vanderbilt-Ingram Cancer Center, Nashville, TN; Donna Hogge, Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, British Columbia, Canada; Scott R. Solomon, The Leukemia Program at Northside Hospital Cancer Center Institute, Atlanta, GA; Richard M. Stone, Dana-Farber Cancer Institute, Boston, MA; Dale L. Bixby, University of Michigan, Grass Lake, MI; Gary J. Schiller, University of California-Los Angeles, Los Angeles; Matthew J. Wieduwilt, University of California-San Diego, La Jolla; Kamalika Banerjee, Michael Chiarella, Arthur C. Louie, Jazz Pharmaceuticals, Palo Alto; Bruno C. Medeiros, Stanford University School of Medicine, Stanford, CA; and Antje Hoering, Cancer Research and Biostatistics, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127025PMC
September 2018

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

N Engl J Med 2018 Jun 2;378(25):2386-2398. Epub 2018 Jun 2.

From the University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., H.M.K.); Memorial Sloan Kettering Cancer Center (E.M.S., M.S.T.) and Weill Cornell Medical College (G.J.R.), New York; Institut Gustave Roussy, Villejuif (S.B., C.W.), and Centre Hospitalier Universitaire Bordeaux, Bordeaux (A.P.) - both in France; Northwestern University, Chicago (J.K.A.); Ohio State University Wexner Medical Center, Columbus (A.S.M.); Sylvester Comprehensive Cancer Center, University of Miami, Miami (R.S.); University of Texas Southwestern Medical Center, Dallas (R.H.C.); University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco (G.N.M.), and City of Hope Medical Center, Duarte (A.S.S.) - both in California; University of Colorado School of Medicine, Aurora (D.A.P.); Sarah Cannon Research Institute, Nashville (W.D.); Massachusetts General Hospital Cancer Center (A.T.F.) and Dana-Farber Cancer Institute (R.M.S.), Boston, and Agios Pharmaceuticals, Cambridge (S.C., H.W., V.Z., K.E.Y., S.M.K., H.Y., D.D., B.F., M.G., H.L., S.A., B.W., E.C.A.) - all in Massachusetts; University of Alabama at Birmingham, Birmingham (H.P.E.); Johns Hopkins University, Baltimore (G.T.P.); Washington University School of Medicine, St. Louis (G.L.U.); Mayo Clinic, Jacksonville, FL (J.M.F.); Oregon Health and Science University Knight Cancer Institute, Portland (E.T.); Hollings Cancer Center, Medical University of South Carolina, Charleston (R.K.S.); Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Mayo Clinic, Phoenix, AZ (J.L.S.); and Cleveland Clinic, Cleveland (M.A.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1716984DOI Listing
June 2018

Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape.

Ther Adv Hematol 2017 Jun 21;8(6):185-195. Epub 2017 Apr 21.

Medical University of South Carolina, Charleston, SC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620717703012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424861PMC
June 2017

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.

J Clin Oncol 2015 Apr 2;33(11):1252-7. Epub 2015 Mar 2.

Richard M. Stone, Emanuele Mazzola, and Donna Neuberg, Dana-Farber Cancer Institute, Boston; Ante S. Lundberg, Antisoma, Cambridge, MA; Steven L. Allen, Hofstra North Shore-Long Island Jewish School of Medicine, Lake Success; Meir Wetzler, Roswell Park Cancer Institute, Buffalo; Martin S. Tallman, Memorial Sloan Kettering Cancer Center, New York, NY; Arnaud Pigneux, Hopital Haut-Leveque, Pessac, France; Robert K. Stuart, Medical University of South Carolina, Charleston, SC; David Rizzieri, Duke University Medical Center, Durham; Bayard Powell, Wake Forest University Comprehensive Cancer Center, Winston Salem, NC; Harry P. Erba, University of Michigan Health System, Ann Arbor, MI; Lloyd Damon, University of California San Francisco, San Francisco, CA; Jun-Ho Jang, Samsung Medical Center, Seoul, Korea; Krzysztof Warzocha, Institute of Hematology and Transfusiology, Warsaw, Poland; Támas Masszi, Szent Istvan and Szent Laszlo Corporate Hospital, Budapest; Miklos Egyed, Kaposi Mor County Teaching Hospital, Kasposvar, Hungary; Mikkael A. Sekeres, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Heinz-August Horst, Universitatsklinikum Schleswig-Holstein, Kiel, Germany; Dominik Selleslag, Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium; Scott R. Solomon, Blood and Marrow Transplant Program and Northside Hospital, Atlanta, GA; and Parameswaran Venugopal, Rush University Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/02/26/JCO.2014.57
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.0952
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.0952DOI Listing
April 2015

Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors.

J Immunol 2015 Feb 16;194(4):1434-45. Epub 2015 Jan 16.

Department of Microbiology and Immunology, Hollings Cancer Center and Children's Research Institute, Medical University of South Carolina, Charleston, SC 29425;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1402382DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323931PMC
February 2015

Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Leuk Lymphoma 2015 Mar;56(3):645-9

Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina , Charleston, SC , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.935369DOI Listing
March 2015

Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?

Curr Hematol Malig Rep 2013 Jun;8(2):156-62

Hollings Cancer Center, Medical University of South Carolina, 96 Jonathan Lucas Street, MSC 635 CSB 903, Charleston, SC 29425, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-013-0158-1DOI Listing
June 2013

Vosaroxin : a novel antineoplastic quinolone.

Expert Opin Investig Drugs 2012 Aug 23;21(8):1223-33. Epub 2012 Jun 23.

Medical University of South Carolina, Hollings Cancer Center, 96 Jonathon Lucas St, MSC 635 CSB 903, Charleston, 29425, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2012.699038DOI Listing
August 2012

Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients.

Leuk Lymphoma 2012 Dec 31;53(12):2444-8. Epub 2012 May 31.

Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.3109/10428194.2012.69
Publisher Site
http://dx.doi.org/10.3109/10428194.2012.691483DOI Listing
December 2012

Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.

Transfusion 2012 Nov 8;52(11):2375-81. Epub 2012 Mar 8.

Department of Medicine, Division of Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina 29425-6350, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1537-2995.2012.03579.x
Publisher Site
http://dx.doi.org/10.1111/j.1537-2995.2012.03579.xDOI Listing
November 2012

Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents.

Am J Hematol 2011 Aug 31;86(8):699-701. Epub 2011 May 31.

Division of Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.22054DOI Listing
August 2011

Helical tomotherapy for extramedullary hematopoiesis involving the pericardium in a patient with chronic myeloid leukemia.

Jpn J Radiol 2010 Jul 27;28(6):476-8. Epub 2010 Jul 27.

Department of Radiation Oncology, Medical University of South Carolina, 169 Ashley Avenue, Charleston, SC 29425, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11604-010-0452-yDOI Listing
July 2010

Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.

J Clin Oncol 2010 Feb 21;28(5):815-21. Epub 2009 Dec 21.

Cancer Therapy and Research Center at The University of Texas Health Science Center, 7979 Wurzbach Rd, Mail Code 8026, Urschel Tower, Suite 600, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.24.2008DOI Listing
February 2010

Tetraploidy and 5q deletion in myelodysplastic syndrome: a case report.

Cancer Genet Cytogenet 2008 May;183(1):64-8

Department of Pathology and Laboratory Medicine, Medical University of South Carolina, 165 Ashley Ave, Ste. 309, Charleston, SC 29425, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S016546080800098
Publisher Site
http://dx.doi.org/10.1016/j.cancergencyto.2008.01.022DOI Listing
May 2008

Proximal esophageal stenosis in head and neck cancer patients after total laryngectomy and radiation.

ORL J Otorhinolaryngol Relat Spec 2008 9;70(4):229-35. Epub 2008 May 9.

Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC 29425, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000130870DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670489PMC
August 2008

Long-term survival following salvage reirradiation with concurrent chemotherapy for recurrent head and neck cancer.

J S C Med Assoc 2008 Feb;104(2):36-9

MUSC, 169 Ashley Avenue, Charleston, SC 29425, USA.

View Article

Download full-text PDF

Source
February 2008

Salivary gland neoplasms.

Curr Treat Options Oncol 2004 Feb;5(1):11-26

Head and Neck Tumor Program, Hollings Cancer Center, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-004-0002-xDOI Listing
February 2004

Oral cancer treatment.

Curr Treat Options Oncol 2003 02;4(1):27-41

Head and Neck Tumor Program, Hollings Cancer Center, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-003-0029-4DOI Listing
February 2003